banner2013d

Vaccines

dreamstime_11953677 dreamstime_1009589
BMI’s technology has the potential to generate vaccines against pathogens for which no effective vaccine exists, improve on the limited protection of previously tried human and veterinary vaccines, and develop therapeutic vaccines that can be given after the onset of disease to supplement the natural response of the immune system. BMI is targeting a select mix of human and veterinary diseases that have a spectrum of characteristics that argue in favor of their pursuit in vaccine development such as applicability of its vaccine technology, market size, and worldwide need. Many of the programs have cross platforms for both human and veterinary applications and thus offer enhanced synergy for the inputted research and development effort.

For further information, please contact: Dr. Gregory J. Tobin:  tobin@bmi-md.com

Research & Development

pone_0020130_g003Globally, influenza is responsible for 250,000 to 500,000 deaths annually and is considered one of the most important respiratory pathogens of humans. In the majority of the past ten years, H3N2 has dominated in prevalence of infection and disease over H1N1, H2N2, and influenza B. In the United States alone, approximately 5–20% of the population contracts influenza illnesses leading to about 240,000 hospitalizations and 40,000 deaths with the majority due to H3N2. In addition to morbidity and mortality, influenza causes an annual economic impact in the range of $80B in this country alone. Click here to learn more .

Company News

blk triangleFall 2012: BMI has been awarded a contract from the Henry M. Jackson Foundation for the Advancement of Military Medicine.
blk triangleSpring 2012: BMI announces award of a grant from the Bill and Melinda Gates Foundation Grand Challenges Exploration Poliovirus Eradication program.
blk triangleJune 2011: BMI announces collaborative research agreement with Crucell-BV for development of a universal influenza vaccine
blk triangleNov. 2010: BMI announces collaborative research agreement with GSK-Biologicals for development of an immune refocused vaccine for respiratory infection
blk triangleSept 2010: BMI is awarded a Qualifying Therapeutic Discovery Project Award
blk triangleJune 2010: BMI is awarded a Small Business Innovative Research Grant from the NIH for vaccine development
blk triangleNov. 2009: BMI is a prime contractor in the Fundamentals of Biology Program of DARPA/DSO for the study of modularity in biological systems